Aztreonam

證據等級: L5

預測適應症: 10 個

Aztreonam: From Gram-Negative Bacterial Infections to Gonococcal Urethritis

One-Sentence Summary

Aztreonam is a monobactam antibiotic historically used against serious Gram-negative bacterial infections. TxGNN generated 10 candidate new indications for this drug; of these, only Gonococcal Urethritis is backed by real clinical and literature evidence — 1 completed Phase 2/3 trial and 8 publications (including one historical RCT). The nine other top-scoring candidates (e.g., hyperamylasemia, congenital analbuminemia, polyclonal hyperviscosity syndrome) have no supporting evidence and no plausible mechanism, and are rated L5 / Hold. This report focuses on the one indication with an actionable evidence base.

Quick Overview

Item	Content
Original Indication	Gram-negative bacterial infections (monobactam antibiotic class) — not formally recorded in this evidence pack
Predicted New Indication	Gonococcal Urethritis
TxGNN Prediction Score	99.59%
Evidence Level	L2
Germany Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed formal mechanism-of-action documentation for aztreonam is currently a data gap in this evidence pack. However, based on the pharmacological information available (drawn from the repurposing rationale), aztreonam is a monocyclic β-lactam (monobactam) antibiotic that inhibits penicillin-binding protein 3 (PBP3) in Gram-negative bacteria, blocking cell wall synthesis. Neisseria gonorrhoeae is a Gram-negative diplococcus, so this is a direct extension of aztreonam's known antibacterial spectrum rather than a novel or speculative mechanism.

This is not a cross-disease repurposing story in the traditional sense — it is closer to indication expansion within the same pharmacological class of activity (Gram-negative bactericidal action). The clinical rationale is driven by the global antimicrobial resistance (AMR) crisis: cephalosporins are now the only consistently reliable class against N. gonorrhoeae, and reevaluating older, underused antibiotics such as aztreonam is being actively pursued as a stopgap therapy.

By contrast, the model's top-ranked prediction (hyperamylasemia, score 99.73%) and several other high-scoring candidates (congenital analbuminemia, polyclonal hyperviscosity syndrome) have no known mechanistic link to an antibacterial cell-wall synthesis inhibitor and zero supporting clinical or literature evidence — these are flagged internally as likely embedding-space artifacts rather than genuine repurposing signals, and are excluded from further development (Hold).

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03867734	Phase 2/3	Completed	32	Open-label demonstration study of aztreonam for pharyngeal gonorrhea, motivated by the CDC-designated urgent AMR threat of antimicrobial-resistant N. gonorrhoeae; reevaluates an older antibiotic as cephalosporin resistance emerges.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
3095216	1986	RCT	Genitourinary Medicine	Single 1g IM dose cleared N. gonorrhoeae in 61 men and 26 women at all sites (except one pharyngeal case); well tolerated, effective against both penicillin-sensitive and -resistant strains.
33077658	2020	Single-arm clinical trial	Antimicrobial Agents and Chemotherapy	Single-dose 2g IM aztreonam evaluated as a repurposed treatment for gonorrhea amid the threat of ceftriaxone resistance; companion publication to NCT03867734.
6225808	1983	Cohort/Therapeutic	Journal of Infectious Diseases	Demonstrated effectiveness of aztreonam against penicillinase-producing (penicillin-resistant) gonococci (PPNG).
3157346	1985	Cohort/Therapeutic	Antimicrobial Agents and Chemotherapy	1g IM aztreonam compared with 2g IM spectinomycin for uncomplicated gonorrhea; no treatment failures with either drug.
6438364	1984	Cohort/Bacteriological-clinical	Japanese Journal of Antibiotics	Bacteriological and clinical evaluation of aztreonam in 30 men with gonorrheal urethritis, including PPNG strains.
3937450	1985	Cohort/Therapeutic	Hinyokika Kiyo (Acta Urologica Japonica)	Epidemiologic and one-shot therapeutic study of aztreonam in gonorrheal infections in Japan.
6226596	1983	Cohort/Therapeutic	Giornale Italiano di Dermatologia e Venereologia	Study of aztreonam in patients with acute gonococcal urethritis.
11406757	2001	Surveillance/Resistance	Journal of Infection and Chemotherapy	Documents emergence of cephem- and aztreonam-highly-resistant N. gonorrhoeae not producing beta-lactamase — an important resistance-monitoring caveat for this indication.

Germany Market Information

Aztreonam currently has no marketing authorization in Germany under this evidence pack (0 authorizations, status: Not marketed). No product-level dosage form or label data is available for review.

Safety Considerations

Please refer to the package insert for safety information. No drug interaction data was returned for this query (query status: not found).

Note: A blocking data gap has been identified — TFDA/BfArM label warnings and contraindications are not yet available, which prevents this candidate from entering the S1 initial safety review stage. This must be resolved before any further development decision is finalized.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Aztreonam's antibacterial activity against N. gonorrhoeae is directly explained by its known mechanism (PBP3 inhibition) rather than a novel repurposing hypothesis, and is supported by one historical RCT plus a completed modern Phase 2/3 demonstration trial (NCT03867734) conducted specifically to address emerging cephalosporin resistance. However, most supporting literature predates modern resistance patterns (1983–1986), and the recent trial has a small, non-randomized sample (n=32).

To proceed, the following is needed:

TFDA/BfArM package insert data (warnings, contraindications) — currently a blocking gap preventing S1 safety review
Formal MOA documentation from DrugBank to replace the current data gap
Updated resistance surveillance data on cross-resistance between aztreonam and third-generation cephalosporins in contemporary N. gonorrhoeae isolates
A larger randomized controlled trial (particularly addressing pharyngeal eradication rates) to upgrade evidence beyond the current single small trial
Regulatory/market feasibility assessment, given 0 current marketing authorizations in Germany
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.